NCT00585052: A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer |
|
|
| Terminated | 2 | 11 | US | Paclitaxel, Abraxane, Taxol, Lovastatin, Mevacor, Altoprev | University of Iowa | Ovarian Cancer | 02/10 | 06/13 | | |
NCT00407563: Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer |
|
|
| Completed | 2 | 48 | US | Bevacizumab, Avastin, Abraxane, albumin-bound paclitaxel | Accelerated Community Oncology Research Network, Genentech, Inc., Celgene Corporation | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | 02/11 | 02/11 | | |
NCT00466960: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy |
|
|
| Completed | 2 | 21 | US | sargramostim, GM-CSF, Leukine, Prokine, paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, laboratory biomarker analysis, immunologic technique, immunological laboratory methods, laboratory methods, immunological | University of Washington, National Cancer Institute (NCI) | Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer | 07/11 | | | |
NCT00499252: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
|
|
| Completed | 2 | 51 | US | Paclitaxel Albumin-Stabilized Nanoparticle Formulation, ABI 007, ABI-007, Abraxane | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma | 07/11 | | | |
NCT00466986: Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer |
|
|
| Completed | 2 | 40 | US | Abraxane | Southeastern Gynecologic Oncology, Celgene Corporation | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 10/11 | 10/11 | | |
